Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells

Rebekka Duhen(Oregon Health & Science University), Andrew D. Weinberg(Providence Portland Medical Center)
Nature Communications
February 16, 2021
Cited by 154


Related Papers